David is an industry veteran and most recently served as Seagen’s Chief Executive Officer and as a member of its Board of Directors. Under his leadership, Seagen significantly grew its portfolio of innovative cancer medicines and was acquired for more than $43 billion by Pfizer in December 2023. Prior to Seagen, he served as Novartis

Felice Verduyn-van Weegen is a Partner in the EQT Life Sciences team. Felice worked for LSP from 2015 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences. Next to Agomab, Felice is on several company boards for EQT life sciences, including Amolyt pharma and Evommune. Prior to joining LSP, Felice

Angelika is a purpose driven physician scientist with over 20 years of drug development expertise at Novartis, Gilead, Genentech and Amgen currently serving as the Development Unit Head of Immunology at Novartis. She earned her MD/PhD from the University of Freiburg, Germany, conduced her postdoctoral research at The Scripps Research Institute in La Jolla and

Ohad is a Partner at Pontifax, where he is focused on scouting and project evaluation. He also serves on the board of several of Pontifax’s portfolio companies including AgomAb, Step Pharma and Adcendo. Ohad obtained his MSc in Biology from Tel-Aviv University.

Ming Fang is a Managing Director at Redmile Group, LLC, a healthcare-focused investment firm. Prior to joining Redmile in 2016, Ming worked in the healthcare space as an investor at Safeguard Scientifics, a consultant at McKinsey & Company and ZS Associates, and an operator at Gilead Sciences. He received a B.A. in Computer Science from